US FDA warns King on misleading claims in Embeda news releases
This article was originally published in Scrip
Executive Summary
The US FDA has warned King Pharmaceuticals that video news releases announcing approval of the company's long-acting opioid Embeda extended-release (morphine sulphate plus naltrexone hydrochloride) are false, misleading and "grossly" minimise the drug's potential serious risks.